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Abstract
Background: ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin motifs) is a member of the
ADAMTS family of metalloproteases. Here, we investigated mRNA and protein levels of ADAMTS-1 in normal and
neoplastic tissues using qPCR, immunohistochemistry and immunoblot analyses, and we addressed the role of
ADAMTS-1 in regulating migration, invasion and invadopodia formation in breast tumor cell lines.
Results: In a series of primary breast tumors, we observed variable levels of ADAMTS-1 mRNA expression but lower
levels of ADAMTS-1 protein expression in human breast cancers as compared to normal tissue, with a striking
decrease observed in high-malignancy cases (triple-negative for estrogen, progesterone and Her-2). This result
prompted us to analyze the effect of ADAMTS-1 knockdown in breast cancer cells in vitro. MDA-MB-231 cells with
depleted ADAMTS-1 expression demonstrated increased migration, invasion and invadopodia formation. The
regulatory mechanisms underlying the effects of ADAMTS-1 may be related to VEGF, a growth factor involved in
migration and invasion. MDA-MB-231 cells with depleted ADAMTS-1 showed increased VEGF concentrations in
conditioned medium capable of inducing human endothelial cells (HUVEC) tubulogenesis. Furthermore, expression
of the VEGF receptor (VEGFR2) was increased in MDA-MB-231 cells as compared to MCF7 cells. To further determine
the relationship between ADAMTS-1 and VEGF regulating breast cancer cells, MDA-MB-231 cells with reduced
expression of ADAMTS-1 were pretreated with a function-blocking antibody against VEGF and then tested in
migration and invasion assays; both were partially rescued to control levels.
Conclusions: ADAMTS-1 expression was decreased in human breast tumors, and ADAMTS-1 knockdown stimulated
migration, invasion and invadopodia formation in breast cancer cells in vitro. Therefore, this series of experiments
suggests that VEGF is involved in the effects mediated by ADAMTS-1 in breast cancer cells.
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Background
Extracellular matrix (ECM) components are involved in
various aspects of tumor biology, including metastatic
events. The ECM provides solid support to cells as well
as a supply of cytokines and growth factors [1,2]. Cancer
progression depends not only on the new abilities gained
by neoplastic cells but also on the interaction between
cells and their microenvironment [3]. ECM components
are cleaved by proteases during physiological and patho-
logical processes, and protease-induced breakdown of the
ECM is essential for cancer cells to move through tissue
barriers [4].
ADAMTS-1 (a disintegrin and metalloprotease with
thrombospondin motifs) is a member of the ADAMTS
family of metalloproteases. This secreted protease partici-
pates in various biological processes, such as inflamma-
tion, angiogenesis and development of urogenital system
[5-8]. ADAMTS-1 has specific substrates that include mo-
dular proteoglycans, such as versican, aggrecan and brevi-
can [9]. Despite the suggested roles for ADAMTS-1 in
tumor invasion and metastasis, the effects of this molecule
during cancer progression remain controversial. In 2008,
Rocks et al. [10] showed that ADAMTS-1 contributes to
tumor development by attracting fibroblasts and remode-
ling the extracellular matrix. Furthermore, some authors
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have shown that ADAMTS-1 is upregulated in pancrea-
tic cancers with metastatic phenotypes [11]. On the other
hand, decreased ADAMTS-1 expression has been descri-
bed in human malignancies [12]. As a result, this protease
was initially thought to inhibit angiogenesis in cancer and
therefore act as an anti-cancer molecule [6] via the bloc-
kade of VEGFR2 phosphorylation by directly binding and
sequestrating VEGF165 [7].
Here, we analyzed ADAMTS-1 mRNA expression in
60 human breast tumors, protein localization in 59 hu-
man samples and protein expression in 56 human sam-
ples, including normal and neoplastic tissues. To further
evaluate the role of ADAMTS-1 in tumor biology, we
studied the role of this protease in the regulation of mi-
gration and invasion in MDA-MB-231 and MCF7 breast
cancer cells. Knocking down ADAMTS-1 expression
using siRNA increased the migration and invasion of
MDA-MB-231 cells. We also found a relationship bet-
ween ADAMTS-1 and the activity of invadopodia, mem-
brane protrusions related to the initial steps of cancer
invasion. MDA-MB-231 cells with silenced ADAMTS-1
displayed increased VEGF expression in conditioned me-
dium. Furthermore, this conditioned medium containing
higher levels of VEGF induced HUVEC tubulogenesis.
Our findings indicate that the effects of ADAMTS-1 in
tumor invasiveness may be related to the availability of
VEGF.
Results
ADAMTS-1 protein and mRNA expression in primary
breast tumors
Quantitative real-time RT-PCR (qPCR) was used to ana-
lyze mRNA expression level of ADAMTS-1 in 60 primary
breast tumors. ADAMTS-1 transcripts were expressed at
varying levels (ranging from 0.1 to 7.3 AU) in the primary
breast tumors analyzed. We determined a gene expression
cut-off value of 0.7 (median value) that differentiated be-
tween ADAMTS-1 low expression and high expression in
breast tumors. Using this cut-off, 39/60 (65%) of the breast
tumors were classified as ADAMTS-1 low expressors, and
21/60 (35%) were classified as ADAMTS-1 high expres-
sors. The clinicopathological characteristics of the patients
are summarized in Table 1.
Table 2 compares the mean ADAMTS-1 mRNA expres-
sion values in relation to the clinicopathological features
of the 60 breast cancer patients.
Statistical analyses demonstrated that high ADAMTS-1
mRNA expression was significantly associated with ad-
vanced clinical stages (p = 0.006) (Table 2 and Figure 1).
However, there were no significant differences between
ADAMTS-1 mRNA expression and age, tumor size, lymph
node metastasis or the levels of estrogen or progesterone
receptors. Neither overall survival (log-rank test; p = 0.459),
nor disease-free survival (log-rank test; p = 0.481) were
significantly different between patients with low or high
ADAMTS-1 mRNA expression levels (data not shown).
Immunoblot analyses using an antibody raised against
the N-terminus of ADAMTS-1 produced at least four dif-
ferent bands in samples from human patients, with ap-
proximate molecular weights of 110, 80, 70 and 60 kDa
(Figure 2A). Moreover, the levels of ADAMTS-1 expression
Table 1 Patients and tumor samples characteristics
Variable Categories n
Age (years old) < 50 22 (36.7)
≥ 50 38 (63.3)
Stage (TNM) Stage I 2 (3.3)
Stage II 25 (41.7)
Stage III 26 (43.3)
Stage IV 7 (11.7)
Tumor size (cm) < 4.0 21 (35.0)
≥ 4.0 39 (65.0)
Lymph node metastasis No 20 (33.3)
Yes 40 (66.7)
Estrogen receptor Negative 27 (45.0)
Positive 33 (55.0)
Progesterone receptor Negative 33 (55.0)
Positive 26 (43.3)
Missing cases 1 (1.7)
ADAMTS-1 Negative 31 (51.7)
Positive 29 (48.3)
Table 2 ADAMTS-1 expression (median value) according
to clinicopathological features and biomolecular markers
in primary breast tumors
Variable Categories n ADAMTS-1
expression
p value
Age (years old) < 50 22 0.350 MW: 0.534
≥ 50 38 0.475
Stage (TNM) Stage I 2 0.225 KW: 0.006
Stage II 25 0.250
Stage III 26 0.625
Stage IV 7 1.100
Tumor size (cm) < 4.0 21 0.350 MW:0.950
≥ 4.0 39 0.400
Lymph node metastasis No 20 0.450 MW: 0.712
Yes 40 0.350
Estrogen receptor Negative 27 0.350 MW: 0.291
Positive 33 0.600
Progesterone receptor Negative 33 0.550 MW: 0.731
Positive 26 0.350
KW: Kruskal Wallis test.
MW: Mann Whitney test.
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in tumors was lower compared to the expression levels
in adjacent, normal tissues from the same patients, and
this comparison was obtained by calculating the ratio bet-
ween ADAMTS-1 and tubulin expression. The 80 kDa
ADAMTS-1 form produced the strongest band, and its
expression was lower in tumors as compared to normal
adjacent tissues (Figure 2B). No differences were found
among the other three bands when comparing the tumor
samples to normal adjacent tissues (not illustrated).
Immunohistochemistry (IHC) was carried out in sam-
ples from normal tissue; breast cancer tumors of grade
IIA, IIB, IIIA and IIIC; and metastatic lymph nodes, and
we evaluated ADAMTS-1 expression in the tumor cell
cytoplasm and the surrounding stroma (Figure 3A). No
significant differences were observed regarding the stai-
ning area fraction, even in the higher graded tumors
(Figure 3B). However, high-grade tumors (IIIA and IIB)
exhibited a trend towards decreased ADAMTS-1 expres-
sion in comparison to the lower tumor grades.
Next, we compared tumor and normal tissue subgroups,
with tumor samples classified as either 1) estrogen (ER)
and progesterone (PR) receptor positive tumors or 2)
triple-negative tumors (ER-, PR-, Her-2). In triple-negative
tumors, ADAMTS-1 protein expression was reduced in
40% of the cases as compared to both normal tissues and
the ER or PR single-positive samples (Figure 3C).
We then assessed differences in staining intensity with
regard to the ADAMTS-1 distribution among tumor
cells or stroma. The labeling intensity profile (Figure 3D)
showed that the expression of ADAMTS-1 in normal
tissues was prominent in both epithelial cells and stro-
ma. In contrast, ADAMTS-1 staining was discrete or ab-
sent in the tumor stroma, and this discrete or absent
staining pattern was more evident in cases with higher
grades of malignancy.
Effects of ADAMTS-1 expression on cell migration
We also investigated ADAMTS-1 expression levels in
breast tumor cell lines, such as MCF7 and MDA-MB-
231. In these cells, siRNA treatment reduced the ex-
pression of ADAMTS-1. In addition, cell lysates and
conditioned medium were analyzed by immunoblot, and
an 80 kDa band was observed for the conditioned me-
dium from both cell lines (Figure 4), whereas a 40 kDa
band was present predominantly in the cell lysates. In
Figure 1 The relative mRNA expression of ADAMTS-1 in
primary breast tumors according to clinical stage (TNM). The
box plot shows data distributed in relation to the median values for
ADAMTS-1 mRNA expression in 60 primary breast tumors stratified
by clinical stage (p = 0.002). Three stage III cases with ADAMTS-1
expression above 2.0 (2.75, 4.95, 7.3) were excluded from the graphic
for better visualization.
Figure 2 Immunoblot of ADAMTS-1 in tumor (T) and adjacent
normal tissue (N). Four bands were identified as ADAMTS-1
(A, arrows). Ductal carcinomas and matched adjacent tissues were
obtained from twenty-eight patient donors and analyzed. The
80 kDa band/tubulin ratio was significantly lower in tumors as
compared to normal tissues (B). No differences were found among
other bands obtained from neoplastic and normal tissues (not
illustrated). The boxed area shows the 80 kDa bands that were
evaluated by densitometry. The asterisks indicate significant data
(p < 0.05).
Freitas et al. Molecular Cancer 2013, 12:2 Page 3 of 15
http://www.molecular-cancer.com/content/12/1/2
Figure 3 ADAMTS-1 was more abundant in normal tissue stroma as compared to tumor stroma. ADAMTS-1 staining is shown for normal
tissue, invasive ductal carcinoma of grades IIA, IIB, IIIA and IIIC and metastatic lymph nodes (A). When the total area fraction was analyzed by
immunohistochemistry, ADAMTS-1 showed no statistically significant difference in staining between normal and tumor tissues (B). However, a
decreasing trend was observed in high-grade types (IIIA and IIB). Subgroup analysis revealed a significant decrease in ADAMTS-1 expression in
triple negative tumors as compared to normal tissues and ER- or PR-positive tumors (C). The labeling intensity profile (D) shows that the
expression of ADAMTS-1 in normal tissue was prominent in both epithelial cells and stroma. In contrast, ADAMTS-1 staining was discrete or
absent in tumor stroma (D, boxed area), and this discrete or absent staining pattern was more evident in higher grades of malignancy
(D, boxed area). Scale bar: 50 μm.
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addition, the immunoblot illustrated the efficiency of
ADAMTS-1 siRNA knockdown (Figure 4).
Next, the effect of ADAMTS-1 on cell migration was
analyzed using time-lapse imaging. For these experiments,
we utilized shRNA-GFP. Cells were transfected with either
ADAMTS-1 shRNA-GFP or control shRNA-GFP, and
only fluorescent cells were analyzed. We measured the
cell distance from the initial position during a set time
interval, which yielded a mean velocity measurement
(μm/hours). Functional ADAMTS-1 knockdown stimu-
lated the migratory activity of MDA-MB-231 cells, and
these cells presented a mean velocity of 11.74 ± 0.9603 μm/
hour, which was at least 2 times higher than that of the
controls (4.756 ± 0.3993 μm/hour) (Figure 5A-D).
MCF7 cells were used in migration experiments to ad-
dress whether ADAMTS-1 knockdown stimulated migra-
tion in other cell lines, including this non-invasive breast
adenocarcinoma cell line. The mean velocity of the con-
trol cells was 6.479 ± 0.4896 μm/hour, whereas the velocity
of the treated cells was 4.676 ± 0.3026 μm/hour. There-
fore, in MCF7 cells, migration was not stimulated and was
instead reduced (Figure 5E-H).
VEGF availability and VEGFR2 expression
As ADAMTS-1 knockdown had different effects in
MCF7 and MDA-MB-231 cells, we next focused on the
mechanisms of ADAMTS-1 that were responsible for
these effects on cell migration. Previous reports have
demonstrated that ADAMTS-1 sequesters VEGF [7].
Thus, we hypothesized that decreasing ADAMTS-1
could increase the availability of VEGF. ELISAs were per-
formed to determine the relative VEGF concentrations
in conditioned medium from either MDA-MB-231 or
MCF7 cells that received ADAMTS-1 siRNA knockdown
treatment. We found that MDA-MB-231 cells in con-
ditioned medium exhibited a statistically significant
increase in VEGF when ADAMTS-1 expression was re-
duced (Figure 6A). Conversely, MCF7 cells in conditioned
medium showed a decrease in VEGF when ADAMTS-1
was silenced using siRNA (Figure 6A).
To address the functional role of decreased ADAMTS-1
levels in MDA-MB-231 cells and the consequent increase
in VEGF, we carried out endothelial tubulogenesis assays.
In MDA-MB-231 cells, ADAMTS-1 expression was
silenced by siRNA, and cells transfected with scrambled
siRNA served as the controls. We obtained conditioned
medium from treated and control cells, and we used this
conditioned medium to induce tubulogenesis in human
endothelial cells (HUVECs).
HUVECs were grown in conditioned medium derived
from MDA-MB-231 cells transfected with ADAMTS-1
siRNA, which created a condition where endothelial
cells could be cultured in media with reduced levels of
ADAMTS-1. In this situation, tubular network forma-
tion was increased as compared to HUVECs grown with
MDA-MB-231 control cells (Figure 6B). We next mea-
sured the length of the tubes formed in the tubulogenesis
Figure 4 ADAMTS-1 expression in cell lysates and conditioned medium from MCF7 and MDA-MB-231 cells. These cells showed reduced
expression of ADAMTS-1 following siRNA treatment. The lysates and conditioned media were analyzed by immunoblot, and an 80-kDa band was
prevalent in the conditioned medium from both cells lines, but more prominently in MDA-MB-231. A 40-kDa smaller band was predominant in
the cell lysates. The immunoblot also illustrated the efficiency of ADAMTS-1 siRNA knockdown. These experiments were carried out at least six
times, and similar results were consistently obtained.
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assays and determined that tube formation with condi-
tioned medium from MDA-MB-231 cells and reduced
ADAMTS-1 expression was increased by 4-fold as com-
pared to the controls (Figure 6C).
Recent reports have also shown that VEGF is related
to the migration of cancer cells [13-18]. Therefore, we
hypothesized that the differences between MCF7 cell
migration and MDA-MB-231 cell migration may be as-
sociated with VEGF expression levels in these cell lines.
Thus, we performed immunoblots to compare VEGFR2
protein expression levels between MCF7 and MDA-MB-
231 cells, and we found that VEGFR2 expression levels
in MDA-MB-231 cells were 1.5-fold higher than in MCF7
cells (Figure 6D).
Figure 5 ADAMTS-1 knockdown increased the velocity of MDA-MB-231 cells, as shown by time-lapse video microscopy. The cells were
transfected with either ADAMTS-1 shRNA-GFP (treated) or non-silencing shRNA-GFP (controls). The fluorescent images were superimposed with
the MDA-MB-231 cell trajectories (A, color tracks) and are illustrated as manual markings on the same cell at different time points. The cells were
recorded after 4.5 hours. The treated cells (B) demonstrated longer trajectories over time as compared to the controls (C). The velocity of the
treated cells was also higher as compared to the controls (D). The asterisks indicate significant data in comparison to the controls (p < 0.001). The
results in B represent the mean ± standard error obtained from 6 experiments. Scale bar: 100 μm. ADAMTS-1 knockdown decreased the velocity
of MCF7 cells, as shown by time-lapse video microscopy. The cells were transfected with either ADAMTS-1 shRNA-GFP (treated) or non-silencing
shRNA-GFP (controls). The fluorescent images were then superimposed with MCF7 cell trajectories (color tracks) and are illustrated as manual
markings on the same cell at different time points (E). The cells were recorded after 4.5 hours. The treated cells (F) presented shorter trajectories
over time as compared to the controls (G), and the velocity of the treated cells was lower in comparison to the controls (H). The asterisks
indicate significant data in comparison to the controls (p < 0.01). The results in D represent the mean ± standard error obtained from 6
experiments. Scale bar: 100 μm.
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VEGF and ADAMTS-1 in cell migration and invasion
To analyze the putative role of VEGF during the cell mi-
gration of ADAMTS-1 siRNA-treated cells, we carried
out cell migration and invasion assays. In these assays, a
VEGF blocking antibody was included. We found that
decreasing ADAMTS-1 levels enhanced both the migra-
tion and invasion of MDA-MB-231 cells. Furthermore,
treatment with aVEGF blocking antibody partially rescued
both cell migration and invasion to the levels obtained
with the control (Figure 7A-B).
Furthermore, ADAMTS-1 knockdown increased invado-
podia activity in comparison to control siRNA-treated cells,
as shown using a fluorescent gelatin assay (Figure 8A-F).
The digested gelatin areas (black spots in the fluorescent
background) were measured using Image J, and MDA-MB-
231 cells treated with ADAMTS-1 siRNAs exhibited at
least a 5-fold increase in digested areas as compared to the
controls.
Discussion
ADAMTS-1 expression decreased in human breast tu-
mors in vivo, mainly in triple negative cases (ER-, PR-,
and Her-2), and ADAMTS-1 knockdown was shown to
stimulate migration, invasion and invadopodia formation
Figure 6 Decreased ADAMTS-1 induced increased VEGF levels in conditioned medium from MDA-MB-231 cells (A) and tubulogenesis in
HUVECs (B). ELISAs were carried out to quantify the VEGF levels in conditioned medium from MDA-MB-231 or MCF7 cells treated with siRNA targeting
ADAMTS-1. MDA-MB-231 cells with reduced ADAMTS-1 expression exhibited a statistically significant increase in VEGF in conditioned medium
(A, right graph). Conversely, MCF7 cells with ADAMTS-1 silenced by siRNA showed a decrease in VEGF levels in conditioned medium (A, left graph).
HUVECs were grown in conditioned medium derived from MDA-MB-231 cells transfected with ADAMTS-1 siRNA. In this situation, tubulogenesis was
induced after 6 hours (B, right panel). The control cells (medium from cells transfected with control siRNA) showed no particular architecture (B, left
panel), whereas tube length was increased in HUVECs treated with conditioned medium derived from MDA-MB-231 cells transfected with ADAMTS-1
siRNA (C). The immunoblot shows the difference in VEGFR expression between MDA-MB-231 and MCF7 cells (D). The asterisks indicate significant data
in comparison to the control (*p < 0.05; ***p<0.001). The panels in (B) represent volumetric renderings from at least 10 confocal optical sections
(software Imaris 7.1). The results in (C) represent the mean ± standard error of three experiments carried out at least three times. Scale bars: 50 μm.
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in breast cancer cells in vitro. Our series of experiments
further suggest that VEGF is involved in these effects of
ADAMTS-1 in breast cancer cells. To our knowledge,
this is the first report establishing this relationship in
human breast cancer cells.
ADAMTS-1 (a disintegrin and metalloproteinase with
thrombospondin motifs) was the first described isoform
in this family [19], and this identification was based
on its elevated expression in cachexia-inducing adeno-
carcinomas in mice. Its multidomain structure links this
secreted protein to various cellular functions; for ex-
ample, it is a potent inhibitor of angiogenesis and plays
an important role in follicular rupture and ovulation
[20] and urogenital development, as demonstrated by
the characteristics of knockout animal models [21].
Altered ADAMTS-1 expression has been reported in
different types of tumors, including breast cancer [11,12].
However, the role of ADAMTS-1 in human breast cancer
is not fully understood and requires further investigation.
Lu et al. (2009) [22] reported that ADAMTS-1 was over-
expressed in 39.7% of breast tumors, and these authors
further demonstrated that ADAMTS-1 overexpression
was associated with an increased risk of bone metas-
tasis. Similarly, we observed variable levels of ADAMTS-1
mRNA expression in a series of primary breast tumors.
However, the immunolocalization of ADAMTS-1 showed
that the expression of this molecule was lower in triple
negative tumors as compared to normal tissues. In this
study, we compared the distribution of ADAMTS-1 in
tumors of different clinical stages, which may explain the
apparent discrepancies between our findings and previous
data. The previous study by Lu et al. analyzed an array of
breast cancer tissues without any consideration for the
stage of the tumor. Therefore, we considered tumor stage
in our analysis and also evaluated the expression of
ADAMTS-1 in the tumor stroma, which was reduced
in higher-staged tumors.
Immunoblots comparing normal tissue and cancer tis-
sue revealed that ADAMTS-1 could be detected in four
different bands: the 110 kDa band, which likely repre-
sents total protein; the 80 kDa, which may characterize
the protease without the pro-domain or the activated
form; and two smaller bands, which may correspond
to activated ADAMTS-1 with additional proteolytic
processing [23,24]. We also observed that the 80 kDa
ADAMTS-1 band was decreased in breast tumors as
compared to adjacent normal tissue samples. Thus, a
reduction in ADAMTS-1, as determined by immunohis-
tochemistry, may represent a decrease in the 80 kDa
ADAMTS-1 band. With regard to the in vitro expression
of ADAMTS-1, both the MCF7 and MDA-MB-231 cell
lines exhibited a prominent ADAMTS-1 80 kDa band in
conditioned medium.
Our results showed that MDA-MB-231 cells with re-
duced ADAMTS-1 expression demonstrated increased
migration, velocity and invasion. In cancer progression,
cell-to-cell detachment from the primary tumor and the
acquisition of a motile phenotype are required for cells
to become invasive and colonize distant organs, thereby
producing a metastasis [25]. The spread of cancer cells
to distant sites in the body is the major cause of death
for cancer patients [26,27], and one major challenge in
cancer therapy is to inhibit the spread of tumor cells
from the primary tumor site to distant organs [28].
Figure 7 Increased cell migration and invasion was stimulated
by decreased expression of ADAMTS-1 and was partially
rescued by a VEGF functional blocking antibody (A, B).
ADAMTS-1 knockdown increased the migration and invasion of
MDA-MB-231 cells. The migration of MDA-MB-231 cells with
ADAMTS-1 silenced by siRNA increased two-fold as compared to the
control. The addition of an anti-VEGF blocking antibody partially
rescued this migration to control levels (A). Invasion assays were
carried out in Boyden chambers coated with Matrigel (B). Cells with
silenced ADAMTS-1 demonstrated three-fold increased levels of
invasion as compared to the controls. Invasion was partially rescued
to control levels in cells pretreated with the VEGF blocking antibody.
The asterisks indicate significant data (*p < 0.05, **p < 0.01,
***p < 0.001). The results represent the mean ± standard error of
three experiments carried out at least three times.
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Previous reports have acknowledged the role of
ADAMTS-1 in cell migration. Krampert et al. (2005) [29]
studied the role of ADAMTS-1 in the healing of skin
wounds. In this model, they observed that ADAMTS-1
played different roles in fibroblast migration depending on
the concentration; a decrease in the level of this protein
stimulated cell migration via the proteolytic activity of
ADAMTS-1.
The effects of ADAMTS-1 knockdown on cell mi-
gration and invasion seem to be related to VEGF, as
MDA-MB-231 cells with reduced ADAMTS-1 expres-
sion showed increased levels of VEGF in conditioned
medium. The relationship between VEGF and ADAMTS-1
was recently reported, and the carboxyl-terminal domain
of ADAMTS-1 was shown to be responsible for binding
and sequestering VEGF [7]. This sequestration of VEGF by
ADAMTS likely inhibits various functions of VEGF, such
as its role in cell migration and invasion.
It has been described that ADAMTS-1 sequesters
VEGF [7]. VEGF is known to enhance migration and
invasion [13,15,16,18]. We then carried out combined
multi-tiered experiments to relate the role of ADAMTS
and VEGF during cell migration and invasion. ADAMTS-
1 knockdown in MDA-MB-231 cells resulted in a decrease
in ADAMTS-1 protease activity in conditioned medium.
Furthermore, cells with reduced ADAMTS-1 expres-
sion demonstrated increased levels of VEGF in condi-
tioned medium. Taken together, these results suggest that
Figure 8 ADAMTS-1 knockdown increased invadopodia formation in MDA-MB-231 cells. Cells were grown on gelatin-Alexa-567 for
6 hours. Image A is a merged image of the blue (nuclei stained with DAPI), red (gelatin-Alexa 567) and green (ADAMTS-1 shRNA-GFP) channels.
Z-projections of 10 optical sections together with orthogonal projections onto XZ (top) and YZ (left) planes were generated (B). The white lines
in (B) indicate points of the XY image projected to generate orthogonal (perpendicular) XZ (top) and YZ (right) planes. Orthogonal projections of
XZ and YZ illustrate digestion at the ventral surfaces of cells. Substrate digestion could be clearly observed when planes XY, XZ and YZ were
viewed in the same volume (C and D, arrowhead). Images C and D were rotated to observe the cell’s ventral surface. The control samples
(treated with non-silencing shRNA-GFP) show discrete matrix digestion (E and F). The area measurements demonstrate that ADAMTS-1
knockdown significantly increased matrix digestion (G). Digested areas in close proximity to the cell ventral surfaces indicate that ADAMTS-1
knockdown induced invadopodia activity. The asterisks indicate significant data in comparison to the control (*p < 0.05, ***p < 0.001). A total of 10
random fields were imaged per experimental group. Scale bar: 10 μm.
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ADAMTS-1 knockdown decreased the presence of this
protease in the conditioned medium of MDA-MB-231
cells, thus preventing the sequestration of VEGF and ren-
dering this growth factor available to exert its cellular ef-
fects, including migration and angiogenesis [13,15,16,18].
To analyze the putative role of VEGF in the cell mi-
gration of MDA-MB-231 cells, we carried out migration
and invasion assays in MDA-MB-231 cells with reduced
ADAMTS-1 expression. To assess the effect of VEGF,
we used a VEGF blocking antibody and found that
ADAMTS-1 knockdown increased migration and inva-
sion, as expected. However, treatment with blocking an-
tibodies partially rescued both cell migration and invasion,
and these results suggest a close relationship between
ADAMTS-1 and VEGF in regulating cell migration and
invasion.
The evidence presented here establishes a relationship
between ADAMTS-1 and VEGF, and our results also indi-
cated that VEGF in conditioned medium from MDA-MB-
231 cells with ADAMTS-1 silenced initiated tubulogenesis
in HUVEC cells. ADAMTS-1 has been described as a pro-
tease with angioinhibitory properties [6] that significantly
blocks VEGFR2 phosphorylation and suppresses endo-
thelial cell proliferation. In addition, the inhibition of
ADAMTS-1-related angiogenesis is related to the
sequestering of VEGF.
VEGF also induces invadopodia formation by increas-
ing the activity of MMP-2, MMP-9 and MT1-MMP [15].
MDA-MB-231 cells with ADAMTS-1 knockdown de-
monstrated increased invasion in Boyden chambers, and
cells with reduced ADAMTS-1 expression also demons-
trated increased invadopodia formation. Therefore, MDA-
MB-231 cells with depleted levels of ADAMTS-1 may
increase the availability of VEGF, which could enhance
invadopodia formation and/or activity.
Various authors have demonstrated invadopodia for-
mation and/or activity in MDA-MB-231 cells using a
variety of approaches. For example, invadopodia activi-
ty in MDA-MB-231 cells has been reported in src-
transformed cells [30,31], in cells cultured on fibronectin
[32] and in cells treated with growth factors [33]. Most
of these studies were carried out in cells grown for at
least 16 hours; in contrast, our results revealed invado-
podia activity over a short timeframe as well as increased
matrix digestion in MDA-MB-231 cells when ADAMTS-
1 is knocked down.
Cancer cells rely on invadopodia to initiate invasive ac-
tivity [30,34], as these formations are enriched with actin
filaments (F-actin) and components needed for actin
assembly, including neural-Wiskott Aldrich Syndrome
protein (N-WASP) and cortactin [30,35-37]. Therefore,
it was not surprising that the functional knockdown of
ADAMTS-1 stimulated the migratory and invasive activity
of MDA-MB-231 cells. On the other hand, ADAMTS-1
knockdown had the opposite effect on MCF7 cells and
reduced their migratory activity. This discrepancy could
be the result of different biological behaviors between
these cell lines. It is well known that MCF7 cells express
estrogen and progesterone receptors, while MDA-MB-231
cells do not. Thus, MDA-MB-231 cells may be more ag-
gressive and invasive as compared to MCF7 cells.
Another possible explanation for these differences in
migration and invasion could be related to VEGF and
VEGF receptor levels. VEGFR2 expression levels in
MDA-MB-231 cells were 1.5-fold higher in comparison
to MCF7 cells, whereas MDA-MB-231 cells with redu-
ced ADAMTS-1 expression showed augmented VEGF
levels in the conditioned medium as compared to the con-
trols. Taken together, these results suggest that MDA-MB-
231 cells possess suitable machinery to interact with
VEGF, a growth factor important for migration and inva-
sion [13,15-18].
Conclusions
Our study was the first to describe lower levels of
ADAMTS-1 protein in triple-negative breast cancer ca-
ses (ER-, PR-, and Her-2), and our immunoblot analyses
indicated that ADAMTS-1 expression was reduced in
tumors in comparison to contralateral normal tissues. In
addition, ADAMTS-1 knockdown stimulated migration,
invasion and invadopodia formation in breast cancer
cells in vitro. This series of experiments suggested that
VEGF is involved in ADAMTS-1 effects on breast can-
cer cells; the diagram depicted in Figure 9 illustrates our
current understanding of ADAMTS-1 in breast cancer.
In normal cells, the extracellular environment is en-
riched with ADAMTS-1, and this protease sequesters
VEGF, thus preventing the effects of this growth factor
on migration and invasion. On the other hand, breast
cancer cells exhibit lower levels of ADAMTS-1 in the
extracellular matrix, and in this scenario, VEGF is no
longer sequestered and becomes freely available to bind
VEGFR, which increases breast cancer cell migration
and invasion. Future investigations are needed to deter-
mine the precise mechanisms by which ADAMTS-1 and
VEGF regulate the invasiveness of cancer cells.
Material and methods
Tissue samples, patient characteristics, RNA extraction
and quantitative real-time PCR (qPCR)
Sixty tumor samples and 20 normal tissues adjacent to
the tumors were obtained from 60 breast cancer patients
at the Hospital do Câncer, A. C. Camargo, São Paulo,
Brazil. Patient age ranged from 23 to 85 years (median
54 years). Tumor samples were dissected to remove any
residual normal tissue before freezing and storing the
samples in liquid nitrogen. The largest diameter of the
tumors was recorded. Microscopic examinations were
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performed to determine the average number of lymph
node metastases in 24 patients. Tumor metastasis into
the lymph nodes was detected in 40 patients. Histopatho-
logical review of all the tumor slides was performed to
confirm the diagnosis. All tumors were classified accord-
ing to the WHO Histological Typing of Breast Tumors.
Infiltrating ductal carcinomas were studied, and the clin-
ical stage was assigned based on the UICC TNM (tumor,
nodes, metastases) staging system.
The Institutional Ethics Committee approved this study,
and all subjects provided informed consent.
Tissue specimens were pulverized under liquid nitro-
gen using a Frozen Tissue Pulverizer (Thermovac Indus-
tries Corporation, Copiague, NY, USA), and total RNA
was extracted using the acid guanidinium thiocyanate-
phenol-chloroform method [38]. Ten micrograms of
total RNA, previously treated with DNaseI, was reverse
transcribed using a High Capacity cDNA Archive Kit
(Applied Biosystems, Carlsbad, CA, USA). qPCR was
performed using an Applied Biosystems 7500 Real-Time
PCR System, and each cDNA sample was analyzed in
duplicate. The PCR reactions were carried out in a total
volume of 25 μl according to the manufacturer’s instruc-
tions for the SYBR Green PCR Core reagent (PE Applied
Biosystems). The following PCR primers were used:
ADAMTS-1 forward, 5’- TGTGGTGTTTGCGGGGGA
AATG-3’ and reverse, 5’- TCGATGTTGGTGGCTCCA
GTT -3’; and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) forward, 5’-CCTCCAAAATCAAGTGGGGC
G-3’ and reverse, 5’-GGGGCAGAGATGATGACCCTT-
3’. The algorithm geNorm was used to define the calibra-
tor gene among the RLP13, HPRT, ACTB and GAPDH
transcripts. As a result, the relative gene expression was
normalized, with GAPDH expression serving as the in-
ternal control. The average value from two groups of 10
normal tissue samples served as a reference sample. The
results were expressed as the n-fold difference in target
gene expression relative to the expression of the GAPDH
gene and the reference sample. The relative expression
was calculated using the 2-ΔΔCT method (CT = fluores-
cence threshold value; ΔCT =CT of the target gene - CT
of the reference gene (GADPH); ΔΔCT =ΔCT of the
tumor sample - ΔCT of the reference sample).
Immunohistochemical analysis
Tissue microarray slides from normal human and breast
cancer samples were obtained from Imgenex (San Diego,
CA; IMH-364). Fifty-nine samples in 4-μm sections were
analyzed, including 35 cases of invasive ductal carcinoma
(IDC), 1 case of sarcomatoid carcinoma, 1 case of intra-
ductal papillary carcinoma, 1 case of atypical medullary
carcinoma, 1 case of metaplastic carcinoma, 1 case of
ductal carcinoma in situ, 10 cases of cancer metastasis
and 9 samples of normal breast tissue adjacent to cancer
tissue. Among these samples, 19 were triple-negative
tumors, with 7 ER- and PR-positive cases. For antigen
Figure 9 Schematic diagram summarizing our current understanding of the role of ADAMTS-1 in breast cancer cells. In normal cells (A),
the extracellular environment is enriched for ADAMTS-1. This protease sequesters VEGF, thus preventing the effects of this growth factor on
migration and invasion. In contrast, tumor cells (B) exhibit lower levels of ADAMTS-1 in the extracellular matrix. In this scenario, VEGF is no longer
sequestered and becomes freely available to bind VEGFR, thereby increasing the migration and invasion of breast cancer cells.
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retrieval, 10 mM of citrate buffer (pH 6.0) with 0.05%
Tween 20 was applied for 30 minutes at 100°C. Then, the
EnVision method (EnVision; Dako Corp., Carpinteria, CA,
USA) was used to analyze the TMAs, and diaminobenzi-
dine served as the chromogen.
ImageJ public domain software (http://rsb.info.nih.gov/ij/)
was used for image analysis. The DAB channel was sepa-
rated by the color deconvolution plugin. The stained areas
were segmented and measured. Quantification involved
either DAB labeling divided by hematoxylin staining or
scoring the labeled intensity of tumor cells or stroma.
Immunohistochemical staining was quantitatively assessed
by three independent observers (VMF, JBA, RGJ) with
minimal interobserver variability (<5%).
Cell lines and transfection
MCF7 and MDA-MB-231 cells were cultured in Dulbecco’s
Modified Eagle’s Medium-F12 (DMEM-F12, Sigma) sup-
plemented with 10% fetal bovine serum (FBS; Cultilab,
Campinas, SP, Brazil). Human umbilical vascular endothe-
lial cells (HUVECs) were cultured in 199 Medium supple-
mented with LSGS (Gibco). The cells were maintained in
25 cm2 flasks in a humidified atmosphere of 5% CO2 at
37°C.
MCF7 and MDA-MB-231 cells were transfected with
commercially available siRNA targeting ADAMTS-1
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA),
according to the manufacturer’s instructions. One day
prior to transfection, subconfluent MCF7 and MDA-MB-
231 cells were cultured in DMEM supplemented with
10% FBS without antibiotic-antimycotic solution. The cells
were incubated with a complex formed by the siRNA
(50 nM), transfection reagent (Lipofectamine 2000, Invi-
trogen) and transfection medium (Opti-MEM I, Invitro-
gen) for 30 h at 37°C.
SureSilencing shRNA plasmids for human ADAMTS-1
with GFP (#KH01149G, SABiosciences, Frederick, MD,
USA) were used for the time-lapse experiments.
Cells transfected with scrambled siRNA or shRNA ser-
ved as controls. These assays were performed in triplicate.
Time-lapse fluorescence microscopy
For the time-lapse fluorescence microscopy, shRNA-
GFP was used to silence ADAMTS-1, as previously des-
cribed. Cells transfected with scrambled interference
RNA served as control. The migration was determined
using a time-lapse fluorescence microscope with an Olym-
pus IX 81 inverted microscope equipped with an Orca R2
CCD camera. Video recordings were conducted using Cell
Observer image software (Olympus). Treated and control
cells were maintained at 37°C in a temperature-controlled
chamber, and images were collected every 5 minutes (over
a total of 4 hours and 30 minutes). MTrack J plugin
(Image J software) was used to measure cell velocity.
Migration and invasion assays
Transwell inserts (with 8 μm pores) in 12-well plates
(BD Biosciences) were used for the migration and inva-
sion assays, where ADAMTS-1 was silenced by siRNA
(Santa Cruz).
In the migration assays, treated and control cells (105)
were plated into the upper chamber containing 1 mL of
DMEM-F12 without serum. The lower chamber was
filled with 1.5 mL of DMEM-F12. After 24 hours in cul-
ture, the cells were fixed with 4% paraformaldehyde and
post-fixed with 0.2% crystal violet in 20% methanol.
Cells on the upper side of the filter were removed with a
cotton swab. The migrating cells on the lower side of
the filter were photographed and counted. These experi-
ments were performed in triplicate and were repeated at
least three times.
For the invasion assays, the filters were coated with
10 μl of Matrigel (10-13 mg/ml). Treated and control
cells (105) were plated into the upper chamber contai-
ning 1 mL of DMEM-F12 without serum. The lower
chamber was filled with 1.5 mL of DMEM-F12. After
48 hours in culture, the cells were fixed and stained. The
cells on the upper side of filter were removed, as des-
cribed above, whereas the invading cells on the lower
side of the filter were photographed and counted. These
experiments were performed in triplicate and were
repeated at least three times.
To determine the role of VEGF in migration and inva-
sion following ADAMTS-1 depletion, cells with silenced
ADAMTS-1 (105) and controls were plated into the
upper chamber containing 1 mL of DMEM-F12 without
serum. The cells were incubated with anti-VEGF bloc-
king antibody (1 μg/ml R&D Systems) or non-specific
mouse IgG (1 μg/ml Millipore). The lower chamber was
filled with 1.5 mL of DMEM-F12 supplemented with
10% of serum. The migration and invasion assays were
conducted as previously described.
ELISA
The level of VEGF in conditioned medium was quan-
tified using MCF7 and MDA-MB-231 cells and the
Human VEGF ELISA kit (Invitrogen). Cells were trans-
fected with either ADAMTS-1 siRNA or control siRNA,
followed by serum starvation for 24 h. The conditioned
media were collected and centrifuged at 1,000 rpm for
5 min at 4°C to remove cellular debris. The conditioned
medium was then analyzed by ELISA according to the
manufacturer’s instructions, and the results were
expressed in pg/mL.
Tubulogenesis assay
ADAMTS-1 expression was silenced by siRNA in MDA-
MB-231 cells, and cells that were transfected with scram-
bled siRNAs served as controls. We obtained conditioned
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medium from treated and control cells, as previously des-
cribed, and this conditioned medium was used to induce
tubulogenesis in human endothelial cells (HUVECs).
Three-dimensional HUVEC cultures were seeded on a
solidified layer of reduced growth factor (RGF) Matrigel,
approximately 1-2 mm in thickness. A round 13-mm
coverslip coated with 20 μl of RGF-Matrigel (Trevigen,
Gaithersburg, MD, kindly provided by Dr. Matthew
Hoffman, NIDCR, NIH) was placed in each well of a
24-well plate. Then, a 100-μl drop of the cell suspension
(3.5 × 105 cells/ml) was placed on top of the Matrigel
and incubated in HUVEC complete medium. After two
hours, the non-adherent cells were washed, and the
complete medium was replaced with serum-free medium
and conditioned for 24 hours with confluent two-dimen-
sional cultures of either control or siRNA-treated MDA-
MB-231 cells. The HUVEC cells remained in these
conditions for 4 hours, followed by fixation in 4% para-
formaldehyde in PBS, permeabilization with 0.5% Triton
X-100, actin staining with rhodamine-phalloidin (Invitro-
gen-Molecular Probes, Eugene, OR) and mounting with
ProLong-DAPI (Invitrogen). The images were acquired
using a Zeiss LSM 510 laser scanning confocal microscope
(Carl Zeiss, Oberkochen, Germany) and analyzed using
Imaris 7.1 (Bitplane Inc, South Windsor, CT, USA) and
Wimasis (Wimasis GmbH, Munich, Germany).
Fluorescent substrate degradation assay
To assess the role of ADAMTS-1 in MDA-MB-231 cell
invadopodia formation, we carried out a fluorescent gel-
atin substrate degradation assay. The substrate was pre-
pared using gelatin conjugated to Alexa 568 (Invitrogen,
Eugene, OR, USA), and the conjugation followed the
manufacturer’s instructions. MDA-MB-231 cells (2 ×
104/mL) that were transfected with ADAMTS-1 shRNA
were plated onto the fluorescent gelatin substrate and
incubated in DMEM with 10% FBS at 37°C for 6 hours.
The control cells were treated with scrambled non-
silencing shRNA. Treated and control cells were fixed in
4% paraformaldehyde in PBS and mounted using Pro-
Long containing DAPI (Invitrogen).
The images were obtained with an Axiophot widefield
fluorescence microscope using a 63x PlanApo 1.4 NA
objective (Carl Zeiss) and acquired using a digital CCD
monochromatic camera (CoolSnap HQ2, Photometrics
Inc, Tucson, AZ, USA). To assess matrix digestion spots
in the fluorescent substrate, at least ten Z sections per
sample field were obtained using a piezoelectric device
(PIFOC, Physik Instrumente, Germany) coupled to the
objective. The microscope and devices were controlled
using the Metamorph Premier 7.6 software (Molecular
Devices, Sunnyvale, CA, USA).
We also examined shRNA-GFP-transfected cells (green
channel) while screening for superimposed digested areas
(dark spots) in the fluorescent gelatin matrix (red channel).
ImageJ was used to measure the degraded areas. The
red channel (fluorescent gelatin) was separately processed
using a threshold tool to calculate the digested area (μm2)
per cell. Volocity software (PerkinElmer, Waltham, MA,
USA) was used to determine the orthogonal projections
and image restorations using deconvolution algorithms.
Western blot
Western blots were carried out to compare ADAMTS-1
levels in MCF7 and MDA-MB-231 cell lysates and con-
ditioned medium and to verify siRNA transfection effi-
ciency. The cells were lysed in RIPA buffer (150 mM
NaCl, 1.0% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM
Tris pH 8.0) containing a protease inhibitor cocktail
(Sigma). After centrifugation (10,000 g) for 10 min at
4°C, the supernatants were recovered and quantified
(BCA kit, Pierce). The samples were resuspended in
Laemmli buffer containing 62.5 mM Tris–HCl pH 6.8,
2% sodium dodecyl sulphate (SDS), 10% glycerol, 5%
mercaptoethanol and 0.001% bromophenol blue. The
conditioned medium (1 mL) was then ethanol-precipi-
tated, and equal amounts (30 μg) of the cell lysates were
electrophoresed on 10% polyacrylamide gels. The pro-
teins were transferred to a Hybond ECL nitrocellulose
membrane (Amersham) and blocked in TBS with 5%
non-fat milk overnight at 4°C. Following one wash in
TBS with 0.05% Tween 20 (TBST), the membranes were
probed with antibodies against ADAMTS-1 (1:1,000,
Abcam 28284), VEGFR2 (1:500, Santa Cruz) and β-actin
(1:2,000, Sigma). The ECL protocol was used to detect
proteins on the membrane.
We also used OncoPair INSTA-Blot Breast Tissue
membranes (IMB-130a, b, c and e; IMGENEX, San Diego,
CA, USA). These ready-to-use PVDF membranes contain
denatured protein lysates from ductal carcinomas and
were matched with adjacent tissues obtained from seven
donors. Each membrane was probed with ADAMTS-1
(Abcam 28284) and alpha-tubulin (Abcam 4074) and
revealed using the ECL protocol.
Statistical methods
The median values of ADAMTS-1 mRNA expression
were in accordance with the clinical and pathological vari-
ables and were compared using the Kruskal-Wallis and
Mann–Whitney tests. For survival analyses, ADAMTS-1
expression was classified as low (<0.7) or high (≥0.7) ac-
cording to its median expression value. The overall sur-
vival and disease-free survival rates were calculated using
the Kaplan-Meier method, and the curves were compared
using the log-rank test. The overall survival and disease-
free survival were calculated from the day of diagnosis to
the date of death and to the date in which recurrence was
detected, respectively. The significance level was set at 5%
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for all tests. The statistical analyses were performed using
SPSS software 15.0 (SPSS Inc., Chicago, IL). The protein
data analyses and statistical significance were obtained
using the Wilcoxon matched test. For in vitro experi-
ments, the data were analyzed using Graph Pad Prism 5
software (Graph Pad Software, Inc., San Diego, CA, USA).
A Student’s t test or ANOVA was used to assess the
differences.
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